Relativity study of thrombopoietin and transforming growth factor-\(\beta_1\) in children with idiopathic thrombocytopenic purpura

Xiu-Li Ju, Hong-Fang Ding, Yan Zhao, Wei Wei and Nian-Zheng Sun

Jinan, China

**Background:** Thrombopoietin (TPO), the major hormone controlling platelet production, and transforming growth factor-beta1 (TGF-\(\beta_1\)), a kind of growth suppressor acting on megakaryopoiesis, have been measured in thrombocytopenias with discordant results. The aim of this study was to explore the relationship between TPO, TGF-\(\beta_1\), and idiopathic thrombocytopenic purpura (ITP) in children.

**Methods:** TPO and TGF-\(\beta_1\) levels in the serum and bone marrow of 45 children with ITP were measured using the enzyme-linked immunosorbent assay (ELISA) method. Twelve healthy children were enrolled as controls.

**Results:** The serum level of TPO was higher in ITP children than in the controls, but no significant difference was observed between them \( (P > 0.05) \). The serum level of TGF-\(\beta_1\) was significantly higher in ITP children than in the controls \( (P < 0.01) \). The serum level of TPO after therapy was lower than that before treatment, but there was no significant difference between them. Some ITP children having a poor response to steroids had a significantly higher serum TPO level than those having good response and the controls. The bone marrow level of TPO was higher in ITP children than in the controls and also higher than the serum level. There was a positive correlation between the serum level and bone marrow level of TPO \( (r = 0.99, P < 0.01) \). The bone marrow level of TGF-\(\beta_1\) was higher than the normal serum level. There was a positive relation between serum level and bone marrow level of TGF-\(\beta_1\) \( (r = 0.80, P < 0.01) \). Before treatment, ITP children had a low platelet count but a high level of TPO. After treatment, when the platelet count increased, the level of TPO reduced. There was a negative correlation between TPO and platelet count \( (r = -0.649, P < 0.05) \) and between TPO and megakaryocyte count \( (r = -0.519, P < 0.05) \).

**Conclusions:** In the pathogenesis of ITP, TGF-\(\beta_1\) is a feedback regulating factor. The levels of TPO and TGF-\(\beta_1\) in serum and bone marrow could help evaluate ITP children’s conditions, estimate prognosis, and enact treatment regimens.


**Key words:** children; thrombocytopenia; thrombopoietin; transforming growth factor-beta1; enzyme-linked immunosorbent assay; relativity

**Introduction**

The injury or dysfunction of megakaryocytes will lead to thrombocytopenia.\(^{1,2}\) During the maturity of megakaryocytes, cytokines play important roles. The stimulating cytokines include thrombopoietin (TPO), interleukin (IL)-3, IL-6 and IL-11;\(^{3,8}\) whereas the inhibiting cytokines include transforming growth factor-beta1 (TGF-\(\beta_1\)), heparin-combined protein, polypeptide and others.\(^{9,10}\) In this cytokine network which affects the maturity of megakaryocytes, TPO and TGF-\(\beta_1\) are the key modulating factors. Idiopathic thrombocytopenic purpura (ITP) is the most common hemorrhagic disease in children.\(^{11,12}\) The aim of this study was to investigate the relationship between TPO, TGF-\(\beta_1\) and thrombocytopenic disease immunologically and molecule biologically for the diagnosis and treatment of ITP children.

**Methods**

**Patients and treatment**

We studied 45 children with acute ITP from January
Thrombopoietin and transforming growth factor-β₁ in children with idiopathic thrombocytopenic purpura

2000 to December 2001, of whom 26 were boys and 19 girls, aged from 5 months to 12 years (mean 5.8 years). These patients were treated with prednisone at a dose of 1.5-2.0 mg·kg⁻¹·d⁻¹, tid, po. When their platelet count was normal, the dose was reduced gradually. The period of treatment lasted 4-6 weeks. Twelve healthy children served as controls, 7 boys and 5 girls, aged from 10 months to 11 years (mean 6.5 years).

Assay of TPO and TGF-β₁
The specimen of peripheral venous blood was taken at early morning on an empty stomach and bone marrow through sternum puncture. The levels of TPO and TGF-β₁ in serum and bone marrow were assayed using the enzyme-linked immunosorbent assay (ELISA). The kits of TPO and TGF-β₁ were purchased from Jingmei Biology Company, Beijing, China. The number of peripheral blood platelets and megakaryocytes in bone marrow slides were counted at the same time.

Statistical analysis
All analyses were performed using Statistical Package for the Social Science Software (SPSS, Inc., Chicago, USA). A P value of less than 0.05 was considered statistically significant.

Results
The serum levels of TPO and TGF-β₁ before therapy in ITP patients and controls
The serum level of TPO was higher in the ITP children than in the controls, but no significant difference was noted (Table 1). The serum level of TGF-β₁ was significantly higher in the ITP children than in the controls.

The relationship between effect of steroids therapy and cytokines mass concentration
The serum level of TPO in ITP patients was slightly lower after therapy (23.44 ± 6.41 μg/L) than before treatment. The serum TPO level in ITP patients with a poor response to steroids was significantly higher (35.29 ± 3.29 μg/L) than in those with a good response (21.67 ± 1.47 μg/L) and the controls.

After treatment, the serum TGF-β₁ mass concentration (89.42 ± 2.60 μg/L) was still significantly higher than normal or was not decreased significantly than that before treatment.

The TPO and TGF-β₁ levels of bone marrow and serum before treatment
The TPO and TGF-β₁ levels of serum and bone marrow in 15 ITP children and 6 controls were detected (Table 2). There was a positive correlation between serum level and bone marrow level of TPO (r = 0.99, P < 0.01). There was a positive relation between serum level and bone marrow level of TGF-β₁ (r = 0.80, P < 0.01).

The correlation analysis between the level of serum TPO and blood platelet count, megakaryocyte count in bone marrow
Before treatment, ITP children had a low platelet count (38 ± 23 × 10⁹/L) but a high level of TPO. After treatment, when platelet count increased (133 ± 83 × 10⁹/L), the level of TPO reduced. A negative correlation was observed between TPO and platelet count (r = -0.649, P < 0.05) and between TPO and megakaryocyte count in bone marrow (r = -0.519, P = 0.041). The serum TPO level was significantly higher in some children with a poor response to steroids than in those with a good response. The megakaryocyte count (131.14 ± 120.68/μm²) was lower in the former than in the latter (389.44 ± 317.60/μm²).

Discussion
TPO as one of the most potent stimulators of platelet production is a kind of glycoprotein mainly synthesized by hepatocyte, proximal and distal renal tubule cell, and marrow stromal cell. It has been reported that TPO can startup the formation of megakaryocyte clone, stimulate maturity of megakaryocyte, and support generation of functional platelet when megakaryocyte is cultured in vitro with combined cytokines. [13-15]

The level of TPO is mainly modulated by peripheral blood platelet and bone marrow megakaryocyte. This modulation depends on the intake and disruption of C-MPL, the receptor of TPO in the platelet. The intake of TPO is reduced when serum platelet count is
low, then the serum level of TPO rises, thus promoting the proliferation, differentiation, maturation of megakaryocyte and the generation of platelet. Eventually, this will result in accelerating the intake and degradation of TPO to gain a new balance as a negative feedback effect.

In the present study, we found that before treatment, ITP children had a low platelet count but a high level of TPO. After treatment, however, when the platelet count increased, the level of TPO decreased. There was a negative correlation between TPO and platelet count. The results of this study demonstrated that the number of platelets is an important factor modulating the serum level of TPO. This study also showed a negative correlation between TPO and megakaryocyte count.

TGF-β1, as a polypeptide growth factor has extensive biological effects including immunosuppression, anti-inflammation, and injury repair. TGF-β1 negatively modulates hematopoiesis. Inhibition of CFU-Meg by TGF-β1 has been previously proved by several investigators. By inhibiting the karyokinesis of megakaryocyte, TGF-β1 suppresses the maturity of megakaryocyte and generation of platelet. Our study showed that the serum level of TGF-β1 in ITP children was significantly higher than that of controls because TGF-β1 exists in megakaryocyte and α granules of platelet, and the disruption of megakaryocyte and platelet may result in the release of TGF-β1.

Sakamaki et al. discovered that TGF-β1 not only directly inhibited the formation of CFU-Meg, but also acted on megakaryocyte indirectly through modulating the TPO formation of stromal cells. Bone marrow stromal cell was affected by increased TGF-β1 and produced plentiful TPO mRNA, which was translated into TPO.

Hematopoietic stem cells were affected by TPO and differentiated into megakaryocyte. TGF-β1, combined with the surface receptor of megakaryocyte to inhibit the function of megakaryocyte. A feedback modulating cycle was then formed.

The relation of steroids therapy to the levels of TPO and TGF-β1 proved that the assay of TPO is important for assessing the prognosis of ITP patient. If the result of steroids treatment is not satisfactory, other management should be adopted to avoid the repeated use of steroids and their side-effects.

References

Funding: None.
Ethical approval: This study was approved by the Regional Committee on Medical Research Ethics of Jinan, China.
Competing interest: None declared.
Contributors: JXL proposed the study and wrote the first draft of this paper. All authors contributed to the intellectual content and approved the final version.
Thrombopoietin and transforming growth factor-β₁ in children with idiopathic thrombocytopenic purpura


Received April 21, 2005
Accepted after revision May 24, 2005